Bipolar Disorder Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Nov. 10, 2011 - PRLog -- GlobalData estimates that the global bipolar disorder therapeutics market was valued at $6,242m in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 2.0% over the next eight years, to reach $7,340m by 2018. Atypical antipsychotics, mood stabilizers, and antidepressants are the commonly prescribed drugs for the treatment of bipolar disorder. The slow market growth during the forecast period is attributed to the patent expiry of leading drugs, entry of new drugs, and stable prevalence. The bipolar disorder therapeutics market will witness the patent expiry of leading drugs such as Zyprexa (2011 in the US and Europe, 2015 in Japan), Seroquel (2012), Geodon/Zeldox (2012), Abilify (2014 in Europe, 2015 in the US and 2017 in Japan), and Sapharis/Sycrest (2015). In addition to this, pipeline molecules such as cariprazine, Nuvigil (armodafinil), and Latuda (lurasidone hydrochloride) are expected to be launched in 2013. GlobalData expects that these factors will account for positive growth within the bipolar disorder therapeutics market through 2018.

During 2000-2005, several drugs were approved for the treatment of bipolar disorder, such as Abilify (aripiprazole), Geodon/Zeldox (ziprasidone), Lamictal (lamotrigine), Risperdal (risperidone), Seroquel (quetiapine), Symbyax (olanzapine and fluoxetine combination) and Zyprexa (olanzapine). Increased uptake of these approved drugs resulted in a relatively high growth of the market through the historic period 2005-2010.

The bipolar disorder therapeutics market has moderate unmet needs. This is due to limited awareness
among physicians and patients, and low diagnosis, treatment and compliance rates. The bipolar disorder
therapeutics market has several approved therapies such as mood stabilizers (lithium, valproate, carbamazepine, and lamotrigine), atypical antipsychotics (Seroquel, Abilify, Zyprexa, Geodon/Zeldox and
risperidone), and antidepressants (Symbyax) available for treatment. Alternatively, drugs such as benzodiazepines (lorazepam, clonazepam) and antidepressants (citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline) have off-label usage. The currently prescribed drugs have moderate safety and efficacy. This indicates that the market needs drugs with superior efficacy and safety which exhibit novel mechanisms of action. Therefore, the bipolar disorder therapeutics market is wide open for novel entrants to fulfill the existing unmet need.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....

GlobalData found the bipolar disorder therapeutics pipeline to be strong. It consists of 34 molecules in different phases of development. There are two molecules in the new drug application (NDA) filing stage, 12 molecules in Phase III, eight molecules in Phase II, and the rest of the molecules are in Phase I, preclinical and discovery phase of the pipeline. AZ-004 (Staccato loxapine) and Abilify (aripiprazole) are in the NDA-filing stage in the US and Japan respectively. Moreover, Phase III pipeline molecules such as
cariprazine, Latuda (lurasidone hydrochloride) and Nuvigil (armodafinil) are expected to enter the bipolar disorder market during the forecast period. This is likely to have a positive impact on the bipolar disorder therapeutics market.

GlobalData, the industry analysis specialist, has released its new report, “Bipolar Disorder Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global bipolar disorder market. The report identifies the key trends shaping and driving the global bipolar disorder market and provides insights into the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global bipolar disorder sector. The analysis is constructred using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Bipo...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.